Evidence map›Paper›PMID 27174290›Full record

ArticleEuropean heart journal2016

Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.

Stefan Blankenberg, Veikko Salomaa, Nataliya Makarova, Francisco Ojeda, Philipp Wild, Karl J Lackner, Torben Jørgensen, Barbara Thorand, Annette Peters, Matthias Nauck and 18 more

Open access · bronzeAbstract read
In one paragraph

Article in European heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 5 pooled it
27.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 5 syntheses or guidelines pooled it, 268 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 6 countries.

Stefan BlankenbergUniversity Heart Center Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Hamburg, Germany s.blankenberg@uke.de.
Veikko SalomaaNational Institute for Health and Welfare, Helsinki, Finland.
Nataliya MakarovaUniversity Heart Center Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Hamburg, Germany.
Francisco OjedaUniversity Heart Center Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany.
Philipp WildDepartment of Medicine II, Preventive Cardiology and Preventive Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany University Medical Center of the Johannes Gutenberg-University Mainz, Center for Thrombosis and Haemostasis (CTH), Mainz, Germany German Center for Cardiovascular Research (DZHK), Partner Site Rhein-Main, Mainz, Germany.
Karl J LacknerUniversity Medical Center Mainz, Institute for Clinical Chemistry and Laboratory Medicine, Mainz, Germany.
Torben JørgensenDepartment of Public Health, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark Research Centre for Prevention and Health, Capital Region, Denmark.
Barbara ThorandHelmholtz Zentrum München, German Research Center for Environmental Health, Institute of Epidemiology II, München, Germany.
Annette PetersHelmholtz Zentrum München, German Research Center for Environmental Health, Institute of Epidemiology II, München, Germany German Center for Cardiovascular Research (DZHK e.V.), Partner Site Munich Heart Alliance, München, Germany.
Matthias NauckUniversity Medicine Greifswald, Institute for Clinical Chemistry and Laboratory Medicine, Greifswald, Germany German Center for Cardiovascular Research (DZHK e.V.), Partner Site Greifswald, Greifswald, Germany.
Astrid PetersmannUniversity Medicine Greifswald, Institute for Clinical Chemistry and Laboratory Medicine, Greifswald, Germany German Center for Cardiovascular Research (DZHK e.V.), Partner Site Greifswald, Greifswald, Germany.
Erkki VartiainenChronic Disease Epidemiology and Prevention Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland.
Giovanni VeronesiDepartment of Clinical and Experimental Medicine, Research Centre in Epidemiology and Preventive Medicine, University of Insubria, Varese, Italy.
Paolo BrambillaDepartment of Laboratory Medicine, Hospital of Desio, University of Milano Bicocca, Desio (MB), Italy.
Simona CostanzoIRCCS Istituto Neurologico Mediterraneo Neuromed, Department of Epidemiology and Prevention, Laboratory of Molecular and Nutritional Epidemiology, Pozzilli, Isernia, Italy.
Licia IacovielloIRCCS Istituto Neurologico Mediterraneo Neuromed, Department of Epidemiology and Prevention, Laboratory of Molecular and Nutritional Epidemiology, Pozzilli, Isernia, Italy.
Gerard LindenQueens University of Belfast, UK Clinical Research Collaboration Centre of Excellence for Public Health, Belfast, UK.
John YarnellQueens University of Belfast, Centre for Public Health Belfast, Belfast, UK.
Christopher C PattersonQueens University of Belfast, Centre for Public Health Belfast, Belfast, UK.
Brendan M EverettBrigham and Women's Hospital, Cardiovascular and Preventive Medicine Divisions, Boston, USA.
Paul M RidkerBrigham and Women's Hospital, Cardiovascular and Preventive Medicine Divisions, Boston, USA.
Jukka KonttoNational Institute for Health and Welfare, Helsinki, Finland.
Renate B SchnabelUniversity Heart Center Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Hamburg, Germany.
Wolfgang KoenigGerman Center for Cardiovascular Research (DZHK e.V.), Partner Site Munich Heart Alliance, München, Germany University of Ulm Medical Centre, Department of Internal Medicine II-Cardiology, Ulm, Germany German Heart Centre Munich, Technical University of Munich, München, Germany.
Frank KeeQueens University of Belfast, UK Clinical Research Collaboration Centre of Excellence for Public Health, Belfast, UK.
Tanja ZellerUniversity Heart Center Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Hamburg, Germany.
Kari KuulasmaaNational Institute for Health and Welfare, Helsinki, Finland.
BiomarCaRE Investigators
German Centre for Cardiovascular Research · DEFinnish Institute for Health and Welfare · FIUniversität Hamburg · DEBrigham and Women's Hospital · USIstituto Neurologico Mediterraneo · ITJohannes Gutenberg University Mainz · DEQueen's University Belfast · GBUnited Kingdom Clinical Research Collaboration · GBHelmholtz Zentrum München · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Copenhagen · DKUniversity of Insubria · ITUniversity of Milano-Bicocca · IT

Funding

British Heart Foundation PG/14/9/30632Medical Research Council G0601463
6 · The paper itself

Abstract

aimsOur aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively. METHODS AND

resultsBased on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar.

conclusionIn individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.

Indexed as

Cardiovascular DiseasesBiomarkersEuropeHumansPrognosisProspective StudiesRisk AssessmentRisk FactorsTroponin IBiomarkersTroponin IBiomarker for Cardiovascular Risk Assessment in EuropeCardiovascular riskHigh-sensitivity assayed troponin IMONICA Risk Genetics Archiving and MonographMortality

Identifiers

PMID27174290
PMCPMC4982535
OpenAlexW2377353977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.